Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Sicherheit und Wirksamkeit von pädiatrischen orthopädischen Implantaten (Global POISE)

4. November 2026 aktualisiert von: Kishore Mulpuri, University of British Columbia

Klinisches Nachsorgeprogramm zur prospektiven Beobachtung der Sicherheit und Wirksamkeit von Implantaten

Implant devices are important tools - their use is essential across a number of orthopaedic indications, including hip conditions, trauma and limb deformity.

Given the vital role fixation devices play in maintaining alignment, promoting healthy bone healing and preventing joint degeneration, it is essential to understand the expected lifetime outcomes of these implants, and evaluate their safety and efficacy.

Prospective implant efficacy and safety registries are needed to support this endeavour, especially considering new regulatory requirements from the European Union Medical Devices Regulation (EU MDR) in relation to post-market clinical follow-up (PMCF).

Studienübersicht

Detaillierte Beschreibung

STUDY PROCEDURES Screening Patients will be screened against basic inclusion/exclusion criteria to see if patients may be appropriate for study participation according to any standard of care assessments available, and where appropriate with the site's REB/IRB screening procedures and local regulatory requirements. If a patient is deemed eligible, data outlined throughout this protocol will be collected, de-identified and entered into a Research Electronic Database Capture (REDCap) system managed at BCCH.

Enrollment Patients will be assigned a sequential, unique study number (subject ID) and de-identified data will be entered in the study database. The center number is designated by the BCCH team for each individual investigational site. The patient number will be in sequential order by the patient screening date starting with 001. Once a patient has been assigned a subject ID, the number will not be reused.

Pre-Operative Procedures Once a patient is identified as eligible for an Implant Safety and Efficacy device report, it will be determined whether that patient is already enrolled in one of the existing condition-specific registries. Should participants be enrolled in a condition-specific registry, demographic data, medical history, preoperative clinical data, including any pre-existing infections at or near the operative site, and data on pre-operative radiographs for the relevant underlying diagnosis will have already been prospectively collected under registry procedures. If a patient has not been previously enrolled in a condition-specific registry, the patient will be offered enrollment in both the condition registry and for the purposes of the Implant Safety and Efficacy device report. Demographic data, medical history, preoperative clinical data and data on pre-operative radiographs for the relevant underlying diagnosis will then be collected retrospectively from the medical record.

Required Data Collection:

Operative details in the source documentation will be collected that provide specific information from the subject's surgery such as surgical approach, complications, and unique device identification (UDI) numbers for the implanted device.

The following data will be collected and entered into the registry:

  • Operative data, specific to the technique related to the relevant OrthoPediatrics system/device
  • Assessments of any device-related adverse events
  • Assessment for other adverse events
  • When possible, the UDI number for the device(s) implanted, or information on the device implanted

Follow-up Procedures

Data collected during routine standard of care follow-up visits will be collected as part of this study. The following data will be collected:

  • Radiographs obtained during study clinical evaluations to determine bony union, as well as healing or complications
  • Device-related adverse events
  • Unanticipated device-related serious adverse device effects
  • Information on implant removals not related to an adverse event; degree of bony union just prior to implant removal Unscheduled Visits [if or when needed]

The condition-specific registries are designed to capture every visit that occurs, whether scheduled or unscheduled. An unscheduled visit may occur when an adverse event occurs, or when a patient returns outside of the planned interval window. If an unscheduled visit occurs, the following assessments are to be done:

  • Assessment of any adverse events related to the device
  • Survivorship of the device

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

4000

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Harpreet Chhina, PhD
  • Telefonnummer: 6008 604-875-2000
  • E-Mail: hchhina@cw.bc.ca

Studieren Sie die Kontaktsicherung

Studienorte

    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3N1
        • Rekrutierung
        • BC Children's Hospital
        • Kontakt:
        • Hauptermittler:
          • Anthony Cooper, FRCSC
        • Hauptermittler:
          • Kishore Mulpuri, FRCSC

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

1 Sekunde bis 25 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Anyone who meets the eligibility criteria and is within the age limits listed in the above sections can participate in this study.

Beschreibung

Inclusion Criteria:

  • Patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU. Off-label use is strongly discouraged; however, any and all on- and off-label indications for use of the products in this program will be collected and stratified accordingly
  • Patients must be able to adhere to the required length of follow-up for the endpoints of each individual product
  • Informed consent/assent is required

Exclusion Criteria:

  • Patients with a demonstrated sensitivity to metals
  • Patients with an inability to follow a post-operative regimen

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Longitudinal Observational Group

Pediatric patients indicated for the device-specific indication, per physician discretion and as indicated in the device IFU.

Patient receives a pediatric orthopaedic implant as a part of standard clinical care.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Device related adverse events
Zeitfenster: 2 years post implant insertion

Determine the frequency and severity of device-related adverse events at device-specific end points. All adverse events will be recorded and followed during the study. The frequency and severity of device related adverse events will be analyzed to ensure the device risk profile has not changed.

2 years post implant insertion
Implant survival
Zeitfenster: 2 years post implant insertion

Determine the implant survival rate at post-operative end-point: (lack of revision)

2 years post implant insertion
Implant efficacy
Zeitfenster: 2 years post implant insertion

Efficacy will be assessed by post-operative clinical and radiographic evaluations at each follow-up end-point to assess bone fixation and/or deformity correction.

2 years post implant insertion

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Numeric pain rating scale (NPRS)
Zeitfenster: 2 years post implant insertion

The numeric pain rating scale (NPRS) is a subjective, 11-point numerical scale in which respondents self-report their pain on a scale of 0 (no pain at all) to 10 (worst pain imaginable).

2 years post implant insertion
LIMB-Q Kids
Zeitfenster: 2 years post implant insertion

LIMB-Q Kids is a new patient reported outcome measure (PROM) for children with lower limb deformities.

2 years post implant insertion
PROMIS
Zeitfenster: 2 years post implant insertion

The Patient Reported Outcomes Measurement Information System (PROMIS) measures are self-reported and parent-reported. It includes over 300 measures of global, physical, mental, and social health for adults and children in the general population and those living with a chronic condition. Specifically, the PROMIS Global Health will be administered to all patients while the PROMIS Physical Function - Mobility short form will be administered to those with an implant used in a lower extremity and the PROMIS Physical Function - Upper Extremity short form will be administered to those with an implant used in an upper extremity.

2 years post implant insertion

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Mitarbeiter

Ermittler

  • Studienleiter: Bryn Zomar, PhD, University of British Columbia

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

6. Januar 2022

Primärer Abschluss (Geschätzt)

1. Dezember 2028

Studienabschluss (Geschätzt)

1. Dezember 2029

Studienanmeldedaten

Zuerst eingereicht

17. Dezember 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

2. Mai 2022

Zuerst gepostet (Tatsächlich)

5. Mai 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

9. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

4. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren